Earnings Call Summary | Esperion Therapeutics(ESPR.US) Q1 2024 Earnings Conference
Earnings Call Summary | Esperion Therapeutics(ESPR.US) Q1 2024 Earnings Conference
The following is a summary of the Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript:
以下是Esperion Therapeutics, Inc.（ESPR）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Esperion Therapeutics reported a record Q1 2024 revenue of $137.7 million, thanks to a $100 million litigation-related settlement from DSE.
US net revenue increased by 46% YoY to $24.8 million, powered by a 43% increase in retail prescription equivalents.
The company closed Q1 with $226.6 million in cash and cash equivalents.
Esperion Therapeutics報告稱，2024年第一季度收入創下了創紀錄的1.377億美元，這要歸功於DSE達成的1億美元訴訟相關和解協議。
受零售處方等價物增長43％的推動，美國淨收入同比增長46％，達到2480萬美元。
該公司在第一季度結束時擁有2.266億美元的現金及現金等價物。
Business Progress:
業務進展：
The company received FDA approval for broader labels for NEXLETOL and NEXLIZET in Q1, increasing their potential market to over 70 million patients in the U.S.
Esperion expects a positive decision from the European Commission on their European cardiovascular risk reduction label submissions by the end of Q2 2024.
A partnership with DSE for European tablet production is underway and should be complete by the second half of next year.
New commercial initiatives, such as the 'lipid lurkers' consumer campaign and promotional digital tools, have been launched and positively received.
Esperion intends to maintain their commercial plan and provide regular progress updates.
該公司在第一季度獲得美國食品藥品管理局批准爲NEXLETOL和NEXLIZET提供更廣泛的標籤，將其潛在市場擴大到美國超過7000萬名患者。
Esperion預計，到2024年第二季度末，歐盟委員會將就其提交的歐洲心血管風險降低標籤做出積極決定。
與DSE在歐洲平板電腦生產方面的合作正在進行中，並將於明年下半年完成。
新的商業舉措，例如 “脂質潛伏者” 消費者活動和促銷數字工具，已經啓動並受到好評。
Esperion打算維持其商業計劃並定期提供最新進展。
More details: Esperion Therapeutics IR
更多詳情： Esperion 治療公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。